medalphabetМедицинский алфавитMedical alphabet2078-56312949-2807ООО «Альфмед»10.33667/2078-5631-2021-35-34-37medalphabet-2357Research ArticleСТОМАТОЛОГИЯDENTISTRYРоль повреждения кишечного барьера в развитии псориазаRole of damage to intestinal barrier in development of psoriasisЕкимовИ. Н.EkimovI. N.

Екимов Илья Николаевич - студент VI курса педиатрического факультета.

Омск

Ekimov Ilya N. - 6th year student of Faculty of Pediatrics.

Omsk

ekimov_ilia@mail.ruПравдинаО. В.PravdinaO. V.

Правдина Ольга Валерьевна - кандидат медицинских наук, доцент кафедры дерматовенерологии и косметологии.

Омск

Pravdina Olga V. - PhD Med, associate professor at Dept of Dermatovenereology and Cosmetology.

Omsk

ekimov_ilia@mail.ruФГБОУ ВО Омский государственный медицинский университет Минздрава РоссииРоссияOmsk State Medical UniversityRussian Federation202118122021035Практическая гастроэнтерология (3)3437Copyright © Екимов И.Н., Правдина О.В., 20212021Екимов И.Н., Правдина О.В.Ekimov I.N., Pravdina O.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-alphabet.com/jour/article/view/2357

Нарушения проницаемости интерстициального барьера, в качестве одного из перспективных механизмов формирования и развития псориаза, являются трендом последних десятилетий. При анализе современных работ, посвященных оценке роли повреждения кишечного барьера в развитии псориаза, отмечено несколько способов оценки кишечной проницаемости (в том числе измерение трансэпителиальных электрических реакций при помощи камеры Уссинга, измерение экскреции перорально введенных молекул, определение динамики и кинетики ЛПС кишечных бактерий, иммуногистохимический конфокальный анализ однородных Z-срезов, перпендикулярных клеточной поверхности эпителия и др.). Однако большинство авторов акцентируют внимание на диагностической значимости и доступности определения биомаркеров. Среди описанных биомаркеров наибольшую ценность имеют клаудин-3, фекальный зонулин, α1-антитрипсин, кальпротектин и белок, связывающий жирные кислоты кишечника (I-FABP). Посредством данных методов оценки кишечной проницаемости и результатов исследований ряд авторов практически доказывают корреляцию между нарушением микробиоты кишечника, проницаемостью кишечный барьеров и развитием псориаза, а также его тяжестью. Данное направление является перспективным для изучения в аспекте терапии пациентов с псориазом, которая включает коррекцию микробиоты кишечника и проницаемости кишечной стенки.

Disorders of interstitial barrier permeability as one of the promising mechanisms of psoriasis formation and development is a trend of the last decades. In the analysis of modern works devoted to the evaluation of the role of intestinal barrier damage in the development of psoriasis, several ways of assessing intestinal permeability have been noted (including measurement of transepithelial electrical responses using a Ussing chamber, measurement of excretion of orally injected molecules, determination of dynamics and kinetics of LPS intestinal bacteria, immunohistochemical confocal analysis of uniform Z-sections perpendicular to the epithelial cell surface, etc.). However, most authors emphasize the diagnostic significance and availability of biomarker detection. Among the described biomarkers, claudin-3, fecal zonulin, α1-antitrypsin, calprotectin and intestinal fatty acid binding protein (I-FABP) are the most valuable. Through these methods of assessing intestinal permeability and the results of their studies, a number of authors practically prove the correlation between the violation of the intestinal microbiota, intestinal barrier permeability and the development of psoriasis, as well as its severity. This aspect is promising to the therapy of patients with psoriasis, which includes correction of intestinal microbiota and intestinal wall permeability.

псориазкишечный барьеркишечная проницаемостьбелки плотных контактовэпителиальная защитаклаудин-3фекальный зонулинα1-антитрипсинкальпротектинpsoriasisintestinal barrierintestinal permeabilitydense contact proteinsepithelial protectionclaudin-3fecal zonulinα1-antitrypsincalprotectinReferencesDavis SA, Narahari S, Feldman SR, Huang W, Pichardo-Geisinger RO, McMichael AJ. Top dermatologic conditions in patients of color: an analysis of nationally representative data. J Drugs Dermatol. 2012; 11 (4): 466–73.Davis SA, Narahari S, Feldman SR, Huang W, Pichardo-Geisinger RO, McMichael AJ. Top dermatologic conditions in patients of color: an analysis of nationally representative data. J Drugs Dermatol. 2012; 11 (4): 466–73.Жукова О. В., Касихина Е. И. Эпидемиологические аспекты псориаза у детей. Клиническая дерматология и венерология. 2018; 17 (5): 24–28.Zhukova O. V., Kasikhina E. I. Epidemiological aspects of psoriasis in children. Russian Journal of Clinical Dermatology and Venereology = Klinicheskaya dermatologiya i venerologiya. 2018; 17(5): 24–28. (in Russ.)Гончаров А. А., Долгих О. В. Иммунологические и генетические особенности патогенетической ассоциации псориаза и дисбиоза толстого кишечника. Инфекция и иммунитет. 2021; 11 (2): 237–248. DOI: 10.15789/2220–7619-IAG-1277.Goncharov A. A., Dolgikh O. V. Immunological and genetic features of patho-genetic association between psoriasis and colonic dysbiosis. Russian Journal of Infection and Immunity = Infektsiya i immunitet. 2021; 11 (2): 237–248. DOI: 10.15789/2220–7619-IAG-1277].Hawro T, Maurer M, Hawro M, Kaszuba A, Cierpiałkowska L, Królikowska M, Za-lewska A. In psoriasis, levels of hope and quality of life are linked. Arch Dermatol Res. 2014; 306 (7): 661–6. DOI: 10.1007/s00403–014–1455–9.Hawro T, Maurer M, Hawro M, Kaszuba A, Cierpiałkowska L, Królikowska M, Za-lewska A. In psoriasis, levels of hope and quality of life are linked. Arch Dermatol Res. 2014; 306 (7): 661–6. DOI: 10.1007/s00403–014–1455–9.Олисова О. Ю., Гаранян Л. Г. Эпидемиология, этиопатогенез и коморбидность при псориазе – новые факты. Российский журнал кожных и венерических болезней. 2017; 20 (4): 214–219. DOI: 10.18821/1560–9588–2017–20–4–214–219.Olisova O. Yu., Garanyan L. G. Epidemiology, etiopathogenesis, comorbidity in psoriasis – new facts. Russian Journal of Skin and Venereal Diseases (Rossiyskii Zhurnal Kozhnykh i Venericheskikh Boleznei). 2017; 20 (4). (in Russ.) DOI: 10.18821/1560–9588–2017–20–4–214–219.Гаус О. В., Ливзан М. А. СРК: что мы знаем о симптомах сегодня? Consilium Medicum. 2019; 21 (8): 42–48. DOI:10.26442/20751753.2019.8.190512.Gaus O. V., Livzan M. A. IBS: what do we know about the symptoms today? Consilium Medicum. 2019; 21 (8): 42–48. (in Russ.) DOI:10.26442/20751753.2019.8.190512.Ахмедов В. А., Гаус О. В. Роль кишечной микробиоты в формировании неалкогольной жировой болезни печени. Терапевтический архив. 2019; 91 (2): 143–148. DOI: 10.26442/00403660.2019.02.000051.Akhmedov V. A., Gaus O. V. The role of gut microbiota in the formation of non-al-coholic fatty liver disease. Therapeutic archive. 2019; 91 (2): 143–148. (In Russ.) DOI: 10.26442/00403660.2019.02.000051.Scaldaferri F, Pizzoferrato M, Gerardi V, Lopetuso L, Gasbarrini A. The gut barrier: new acquisitions and therapeutic approaches. J Clin Gastroenterol. 2012; 46 Suppl: S 12–7. DOI: 10.1097/MCG.0b013e31826ae849.Scaldaferri F, Pizzoferrato M, Gerardi V, Lopetuso L, Gasbarrini A. The gut barrier: new acquisitions and therapeutic approaches. J Clin Gastroenterol. 2012; 46 Suppl: S 12–7. DOI: 10.1097/MCG.0b013e31826ae849.Zhao X, Zeng H, Lei L, Tong X, Yang L, Yang Y, Li S, Zhou Y, Luo L, Huang J, Xiao R, Chen J, Zeng Q. Tight junctions and their regulation by non-coding RNAs. Int J Biol Sci. 2021; 17 (3): 712–727. DOI: 10.7150/ijbs.45885.Zhao X, Zeng H, Lei L, Tong X, Yang L, Yang Y, Li S, Zhou Y, Luo L, Huang J, Xiao R, Chen J, Zeng Q. Tight junctions and their regulation by non-coding RNAs. Int J Biol Sci. 2021; 17 (3): 712–727. DOI: 10.7150/ijbs.45885.Perveen I, Rahman MM, Saha M, Rahman MM, Hasan MQ. Prevalence of irritable bowel syndrome and functional dyspepsia, overlapping symptoms, and associated factors in a general population of Bangladesh. Indian J Gastroenterol. 2014;33(3): 265–73. DOI: 10.1007/s12664–014–0447–1.Perveen I, Rahman MM, Saha M, Rahman MM, Hasan MQ. Prevalence of irritable bowel syndrome and functional dyspepsia, overlapping symptoms, and associated factors in a general population of Bangladesh. Indian J Gastroenterol. 2014;33(3): 265–73. DOI: 10.1007/s12664–014–0447–1.Muniz LR, Knosp C, Yeretssian G. Intestinal antimicrobial peptides during ho-meostasis, infection, and disease. Front Immunol. 2012; 3: 310. DOI: 10.3389 fimmu.2012.00310.Muniz LR, Knosp C, Yeretssian G. Intestinal antimicrobial peptides during ho-meostasis, infection, and disease. Front Immunol. 2012; 3: 310. DOI: 10.3389 fimmu.2012.00310.Bramhall M, Zaph C. Mastering gut permeability: New roles for old friends. Eur J Immunol. 2017; 47 (2): 236–239. DOI: 10.1002/eji.201646842.Bramhall M, Zaph C. Mastering gut permeability: New roles for old friends. Eur J Immunol. 2017; 47 (2): 236–239. DOI: 10.1002/eji.201646842.Garcia-Hernandez V, Quiros M, Nusrat A. Intestinal epithelial claudins: expression and regulation in homeostasis and inflammation. Ann NY Acad Sci. 2017; 1397 (1): 66–79. DOI: 10.1111/nyas.13360.Garcia-Hernandez V, Quiros M, Nusrat A. Intestinal epithelial claudins: expression and regulation in homeostasis and inflammation. Ann NY Acad Sci. 2017; 1397 (1): 66–79. DOI: 10.1111/nyas.13360.Rodgers LS, Beam MT, Anderson JM, Fanning AS. Epithelial barrier assembly re-quires coordinated activity of multiple domains of the tight junction protein ZO-1. J Cell Sci. 2013; 126 (Pt 7): 1565–75. DOI: 10.1242/jcs.113399.Rodgers LS, Beam MT, Anderson JM, Fanning AS. Epithelial barrier assembly re-quires coordinated activity of multiple domains of the tight junction protein ZO-1. J Cell Sci. 2013; 126 (Pt 7): 1565–75. DOI: 10.1242/jcs.113399.Ely PH. Is psoriasis a bowel disease? Successful treatment with bile acids and bioflavonoids suggests it is. Clin Dermatol. 2018; 36 (3): 376–389. DOI: 10.1016/j.clindermatol.2018.03.011.Ely PH. Is psoriasis a bowel disease? Successful treatment with bile acids and bioflavonoids suggests it is. Clin Dermatol. 2018; 36 (3): 376–389. DOI: 10.1016/j.clindermatol.2018.03.011.Zhu MJ, Sun X, Du M. AMPK in regulation of apical junctions and bar-rier function of intestinal epithelium. Tissue Barriers. 2018; 6 (2): 1–13. DOI: 10.1080/21688370.2018.1487249.Zhu MJ, Sun X, Du M. AMPK in regulation of apical junctions and bar-rier function of intestinal epithelium. Tissue Barriers. 2018; 6 (2): 1–13. DOI: 10.1080/21688370.2018.1487249.Ayala-Fontánez N, Soler DC, McCormick TS. Current knowledge on psoriasis and autoimmune diseases. Psoriasis (Auckl). 2016; 6: 7–32. DOI: 10.2147/PTT.S64950.Ayala-Fontánez N, Soler DC, McCormick TS. Current knowledge on psoriasis and autoimmune diseases. Psoriasis (Auckl). 2016; 6: 7–32. DOI: 10.2147/PTT.S64950.Hartsock A, Nelson WJ. Adherens and tight junctions: structure, function and connections to the actin cytoskeleton. Biochim Biophys Acta. 2008; 1778 (3): 660.-9. DOI: 10.1016/j.bbamem.2007.07.012.Hartsock A, Nelson WJ. Adherens and tight junctions: structure, function and connections to the actin cytoskeleton. Biochim Biophys Acta. 2008; 1778 (3): 660.-9. DOI: 10.1016/j.bbamem.2007.07.012.Bischoff SC, Barbara G, Buurman W, Ockhuizen T, Schulzke JD, Serino M, Tilg H, Wat-son A, Wells JM. Intestinal permeability – a new target for disease prevention and therapy. BMC Gastroenterol. 2014 Nov; 14: 189. DOI: 10.1186/s12876–014–0189–7.Bischoff SC, Barbara G, Buurman W, Ockhuizen T, Schulzke JD, Serino M, Tilg H, Wat-son A, Wells JM. Intestinal permeability – a new target for disease prevention and therapy. BMC Gastroenterol. 2014 Nov; 14: 189. DOI: 10.1186/s12876–014–0189–7.Grootjans J, Thuijls G, Verdam F, Derikx JP, Lenaerts K, Buurman WA. Non-invasive assessment of barrier integrity and function of the human gut. World J Gastrointest Surg. 2010; 2 (3): 61–9. DOI: 10.4240/wjgs.v2.i3.61.Grootjans J, Thuijls G, Verdam F, Derikx JP, Lenaerts K, Buurman WA. Non-invasive assessment of barrier integrity and function of the human gut. World J Gastrointest Surg. 2010; 2 (3): 61–9. DOI: 10.4240/wjgs.v2.i3.61.Gragg SE, Loneragan GH, Nightingale KK, Brichta-Harhay DM, Ruiz H, Elder JR, Garcia LG, Miller MF, Echeverry A, Ramírez Porras RG, Brashears MM. Substantial within-animal diversity of Salmonella isolates from lymph nodes, feces, and hides of cattle at slaughter. Appl Environ Microbiol. 2013; 79 (15): 4744–50. DOI: 10.1128/AEM.01020–13.Gragg SE, Loneragan GH, Nightingale KK, Brichta-Harhay DM, Ruiz H, Elder JR, Garcia LG, Miller MF, Echeverry A, Ramírez Porras RG, Brashears MM. Substantial within-animal diversity of Salmonella isolates from lymph nodes, feces, and hides of cattle at slaughter. Appl Environ Microbiol. 2013; 79 (15): 4744–50. DOI: 10.1128/AEM.01020–13.Cai J, Chen H, Weng M, Jiang S, Gao J. Diagnostic and Clinical Significance of Serum Levels of D-Lactate and Diamine Oxidase in Patients with Crohn's Disease. Gastroenterol Res Pract. 2019; 2019: 8536952. DOI: 10.1155/2019/8536952.Cai J, Chen H, Weng M, Jiang S, Gao J. Diagnostic and Clinical Significance of Serum Levels of D-Lactate and Diamine Oxidase in Patients with Crohn's Disease. Gastroenterol Res Pract. 2019; 2019: 8536952. DOI: 10.1155/2019/8536952.Kurbatova A., Poluektova E., Demura T., Kuchumova S., Konkov M., Gorev M., Shep-tulin A., Kogan E., Shifrin O. Ivashkin V. Cytokines and tight junction proteins expression changes in patients with irritable bowel syndrome. Gastroenterology. 2012; 142 (5): 807.Kurbatova A., Poluektova E., Demura T., Kuchumova S., Konkov M., Gorev M., Shep-tulin A., Kogan E., Shifrin O. Ivashkin V. Cytokines and tight junction proteins expression changes in patients with irritable bowel syndrome. Gastroenterology. 2012; 142 (5): 807.Fukunishi S, Sujishi T, Takeshita A, Ohama H, Tsuchimoto Y, Asai A, Tsuda Y, Higuchi K. Lipopolysaccharides accelerate hepatic steatosis in the development of nonalcoholic fatty liver disease in Zucker rats. J Clin Biochem Nutr. 2014; 54 (1): 39–44. DOI: 10.3164/jcbn.13–49.Fukunishi S, Sujishi T, Takeshita A, Ohama H, Tsuchimoto Y, Asai A, Tsuda Y, Higuchi K. Lipopolysaccharides accelerate hepatic steatosis in the development of nonalcoholic fatty liver disease in Zucker rats. J Clin Biochem Nutr. 2014; 54 (1): 39–44. DOI: 10.3164/jcbn.13–49.Barzał JA, Szczylik C, Rzepecki P, Jaworska M, Anuszewska E. Plasma citrulline level as a biomarker for cancer therapy-induced small bowel mucosal damage.Barzał JA, Szczylik C, Rzepecki P, Jaworska M, Anuszewska E. Plasma citrulline level as a biomarker for cancer therapy-induced small bowel mucosal damage.Acta Biochim Pol. 2014; 61 (4): 615–31. 26. Reisinger K. W., Derikx J. P., Thuijls G., van der Zee D. C., Brouwers H. A., van Bijnen A. A. Noninvasive measurement of intestinal epithelial damage at time of refeeding can predict clinical outcome after necrotizing enterocolitis. Pediatr Res. 2013; 73: 209–13. DOI: 10.1038/pr.2012.160.Acta Biochim Pol. 2014; 61 (4): 615–31. 26. Reisinger K. W., Derikx J. P., Thuijls G., van der Zee D. C., Brouwers H. A., van Bijnen A. A. Noninvasive measurement of intestinal epithelial damage at time of refeeding can predict clinical outcome after necrotizing enterocolitis. Pediatr Res. 2013; 73: 209–13. DOI: 10.1038/pr.2012.160.Adriaanse M. P., Tack G. J., Passos V. L., Damoiseaux J. G., Schreurs M. W., van Wijck K. Serum I-FABP as marker for enterocyte damage in coeliac disease and its relation to villous atrophy and circulating autoantibodies. Aliment Pharmacol. Ther. 2013; 37: 482–90. DOI: 10.1111/apt.12194.Adriaanse M. P., Tack G. J., Passos V. L., Damoiseaux J. G., Schreurs M. W., van Wijck K. Serum I-FABP as marker for enterocyte damage in coeliac disease and its relation to villous atrophy and circulating autoantibodies. Aliment Pharmacol. Ther. 2013; 37: 482–90. DOI: 10.1111/apt.12194.Aasbrenn M., Lydersen S., Farup P. G. Changes in serum zonulin in individuals with morbid obesity after weightloss interventions: a prospective cohort study. BMC Endocr Disord. 2020; 20 (1): 108. DOI: 10.1186/s12902–020–00594–5.Aasbrenn M., Lydersen S., Farup P. G. Changes in serum zonulin in individuals with morbid obesity after weightloss interventions: a prospective cohort study. BMC Endocr Disord. 2020; 20 (1): 108. DOI: 10.1186/s12902–020–00594–5.Sikora M, Chrabąszcz M, Maciejewski C, Zaremba M, Waśkiel A, Olszewska M, Rudnicka L. Intestinal barrier integrity in patients with plaque psoriasis. J Dermatol. 2018; 45 (12): 1468–1470. DOI: 10.1111/1346–8138.14647.Sikora M, Chrabąszcz M, Maciejewski C, Zaremba M, Waśkiel A, Olszewska M, Rudnicka L. Intestinal barrier integrity in patients with plaque psoriasis. J Dermatol. 2018; 45 (12): 1468–1470. DOI: 10.1111/1346–8138.14647.Sikora M, Chrabąszcz M, Waśkiel-Burnat A, Rakowska A, Olszewska M, Rudnicka L. Clau-din-3 – a new intestinal integrity marker in patients with psoriasis: association with disease severity. J Eur Acad Dermatol Venereol. 2019; 33 (10): 1907–1912. DOI: 10.1111/jdv.15700.Sikora M, Chrabąszcz M, Waśkiel-Burnat A, Rakowska A, Olszewska M, Rudnicka L. Clau-din-3 – a new intestinal integrity marker in patients with psoriasis: association with disease severity. J Eur Acad Dermatol Venereol. 2019; 33 (10): 1907–1912. DOI: 10.1111/jdv.15700.Sikora M, Stec A, Chrabaszcz M, Giebultowicz J, Samborowska E, Jazwiec R, Dadlez M, Olszewska M, Rudnicka L. Clinical Implications of Intestinal Barrier Damage in Psoriasis. J Inflamm Res. 2021; 14: 237–243. DOI: 10.2147/JIR.S 292544.Sikora M, Stec A, Chrabaszcz M, Giebultowicz J, Samborowska E, Jazwiec R, Dadlez M, Olszewska M, Rudnicka L. Clinical Implications of Intestinal Barrier Damage in Psoriasis. J Inflamm Res. 2021; 14: 237–243. DOI: 10.2147/JIR.S 292544.Ahmed A., El Dakrory F., Hendawy S., Shaaban N. Assessment of Serum Level of Claudin-3 and Its Association with Disease Severity in Patients with Psoriasis Vulgaris. The Egyptian Journal of Hospital Medicine, 2021; 83 (1): 1155–1161. DOI: 10.21608/ejhm.2021.161770.Ahmed A., El Dakrory F., Hendawy S., Shaaban N. Assessment of Serum Level of Claudin-3 and Its Association with Disease Severity in Patients with Psoriasis Vulgaris. The Egyptian Journal of Hospital Medicine, 2021; 83 (1): 1155–1161. DOI: 10.21608/ejhm.2021.161770.Haidmayer A, Bosch P, Lackner A, D'Orazio M, Fessler J, Stradner MH. Effects of Probiotic Strains on Disease Activity and Enteric Permeability in Psoriatic Arthritis-A Pilot Open-Label Study. Nutrients. 2020; 12 (8): 2337. DOI: 10.3390/nu12082337.Haidmayer A, Bosch P, Lackner A, D'Orazio M, Fessler J, Stradner MH. Effects of Probiotic Strains on Disease Activity and Enteric Permeability in Psoriatic Arthritis-A Pilot Open-Label Study. Nutrients. 2020; 12 (8): 2337. DOI: 10.3390/nu12082337.

The authors declare that there are no conflicts of interest present.